Abstract: The present invention is drawn to compositions and methods for selectively killing neoplastic cells. Altered viruses are utilized which are capable of replication in neoplastic cells while sparing surrounding normal tissue.

Abstract: A method for killing malignant brain tumor cells in vivo entails providing replication competent herpes simplex virus vectors to tumor cells. A replication competent herpes simplex virus vector, with defective expression of the &ggr;34.5 gene and the ribonucleotide reductase gene, specifically destroys tumor cells, is hypersensitive to anti-viral agents, and yet is not neurovirulent.

Abstract: This invention relates to methods of gene delivery to cells in the nervous system by introducing and expressing gene sequences mediated by herpes simplex virus 1 (HSV-1) vectors with a mutation in a gene for viral replication. The present invention further relates to methods for modulating neuronal physiology and for treating nervous system disorders. The present invention also relates to an animal model for nervous system disorders and to methods for producing such an animal model.

Abstract: The present invention discloses compositions and methods for selective killing neoplastic cells. Retroviral vectors are used to selectively express a gene in neoplastic cells. The gene or gene product targets the cells for selective killing.

Abstract: The present invention discloses compositions and methods for selectively killing neoplastic cells. Retroviral vectors are used to selectively express a gene in neoplastic cells. The gene or gene product targets the cells for selective killing.

Abstract: The invention provides viral vectors (e.g., herpes viral vectors) and methods of using these vectors to treat disease.

Abstract: Eliciting a systemic antitumor immune response, in a patient who presents with or who is at risk of developing multiple metastatic tumors of a given cell type, entails, in one embodiment, inoculating a tumor in the patient with a pharmaceutical composition consisting essentially of (A) a herpes simplex virus (HSV) that infects tumor cells but that does not spread in normal cells and (B) a pharmaceutically acceptable vehicle for the virus, such that an immune response is induced that is specific for the tumor cell type and that kills cells of the inoculated tumor and of a non-inoculated tumor. In another embodiment, the pharmaceutical composition also comprises a defective HSV vector which contains an expressible nucleotide sequence encoding at least one immune modulator. In another embodiment, the pharmaceutical composition contains a second HSV that infects tumor cells but that does not spread in normal cells.

Abstract: Eliciting a systemic antitumor immune response, in a patient who presents with or who is at risk of developing multiple metastatic tumors of a given cell type, entails, in one embodiment, inoculating a tumor in the patient with a pharmaceutical composition consisting essentially of (A) a herpes simplex virus (HSV) that infects tumor cells but that does not spread in normal cells and (B) a pharmaceutically acceptable vehicle for the virus, such that an immune response is induced that is specific for the tumor cell type and that kills cells of the inoculated tumor and of a non-inoculated tumor. In another embodiment, the pharmaceutical composition also comprises a defective HSV vector which contains an expressible nucleotide sequence encoding at least one immune modulator. In another embodiment, the pharmaceutical composition contains a second HSV that infects tumor cells but that does not spread in normal cells.

Abstract: A method for treating a neurofibrosarcoma tumor comprising administration of heparin and an angiostatic steroid is disclosed. Animal models for the growth of neurally-derived tumors and for testing therapeutic agents are also provided.

Abstract: A method for killing malignant brain tumor cells in vivo entails providing replication competent herpes simplex virus vectors to tumor cells. A replication competent herpes simplex virus vector, with defective expression of the .gamma.34.5 gene and the ribonucleotide reductase gene, specifically destroys tumor cells, is hypersensitive to anti-viral agents, and yet is not neurovirulent.

Abstract: A method for treating a neurofibrosarcoma tumor comprising administration of heparin and an angiostatic steroid is disclosed. Animal models for the growth of neurally-derived tumors and for testing therapeutic agents are also provided.

Abstract: A method for killing tumor cells in vivo entails providing replication competent herpes simplex virus vectors to tumor cells. A replication competent herpes simplex virus vector, with an essential herpes simplex virus gene which is driven by a tumor-specific or cell-specific promoter that specifically destroys tumor cells and is not neurovirulent. Also, a method for producing an animal model, by ablating a specific cell type in vivo, entails providing replication competent herpes simplex virus vectors to the animal. Such a vector, with an essential herpes simplex virus gene driven by a cell- or tissue-specific promoter, specifically destroys the target cell type. This method of viral-mediated gene therapy employs cell-specific viral replication, where viral replication and associated cytotoxicity are limited to a specific cell-type by the regulated expression of an essential immediate-early (IE) viral gene product.

Abstract: A method for killing malignant brain tumor cells in vivo entails providing replication competent herpes simplex virus vectors to tumor cells. A replication competent herpes simplex virus vector, with defective expression of the .sub..gamma. 34.5 gene and the ribonucleotide reductase gene, specifically destroys tumor cells, is hypersensitive to anti-viral agents, and yet is not neurovirulent.